- Home
- SKWD vs TRVI Comparison
SKWD vs TRVI Comparison
Compare SKWD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKWD | TRVI |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SKWD | TRVI |
|---|---|---|
| Price | $55.86 | $18.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $64.63 | $21.55 |
| AVG Volume (30 Days) | 455.8K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.81 | 31.91 |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $1,416,541,000.00 | N/A |
| Revenue This Year | $29.54 | N/A |
| Revenue Next Year | $12.64 | N/A |
| P/E Ratio | $25.99 | ★ N/A |
| Revenue Growth | ★ 23.16 | N/A |
| 52 Week Low | $40.60 | $6.93 |
| 52 Week High | $65.69 | $20.22 |
Technical Indicators
Market Signals| Indicator | SKWD | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 51.62 |
| Support Level | $42.50 | $17.49 |
| Resistance Level | $64.23 | $19.89 |
| Average True Range (ATR) | 2.36 | 0.84 |
| MACD | -0.94 | -0.02 |
| Stochastic Oscillator | 14.31 | 42.55 |
Price Performance
Historical ComparisonAbout SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.